Oral Sodium Phosphate Lawsuit
The Food and Drug Administration (FDA) has issued an alert that Oral Sodium Phosphate (OSP) products used for bowel cleansing before a colonoscopy or other procedures may cause acute phosphate nephropathy, a type of kidney injury.
Oral Sodium Phosphate is manufactured by Fleet as an over-the-counter bowel prep and prescribed under the names Visicol and OsmoPrep and the over-the-counter OSP product Fleet Phospho-soda EZ-prep, which can be used as a laxative.
Oral Sodium Phosphate (OSP) Linked to Kidney Injury
Oral Sodium Phosphate (OSP) has been linked to acute phosphate nephropathy, also known as nephrocalcinosis, a serious kidney injury. Nephrocalcinosis occurs due to deposits of calcium-phosphate crystals in the renal tubes that can lead to dialysis or a kidney transplant. Patients with acute phosphate nephropathy may endure renal failure and even death, which may lead to a wrongful death lawsuit.
Patients using OSP may be at risk of kidney injuries even if they did not have any kidney problems and do not have a family history of kidney disease, according to the FDA.